Summary

The North America alpha and beta emitters based radiopharmaceuticals market is expected to reach USD 783.52 million by 2032 from USD 339.33 million in 2024, growing with a substantial CAGR of 11.1% in the forecast period of 2025 to 2032.

Market Segmentation:
North America Alpha and Beta Emitters Based Radiopharmaceuticals Market, By Isotope (Beta Emitters and Alpha Emitters), Sources (Reactor-Produced Isotopes, Generator-Produced Isotopes, and Others), Therapeutic Application (Oncology and Others), Vector Type (Small Molecule Ligands, Peptides, Monoclonal Antibodies, and Others), End User (Hospitals, Radiopharmacies, and Research Institutes), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2032
Overview of North America Alpha and Beta Emitters Based Radiopharmaceuticals Market Dynamics:
Drivers
• Increased efficacy of targeted alpha and beta therapies
• Growing adoption of theranostics in personalized medicine
• Rising clinical demand for alpha-based radiotherapies
Restraints
• Supply chain and scalability challenges from short isotope half-lives
• Stringent regulatory landscape limiting market flexibility
Opportunities
• Surge in R&D activity expanding radiopharmaceutical applications
• Expansion of Lu-177-PSMA therapy in prostate cancer treatment
Market Players:
The key players operating in the North America alpha and beta emitters based radiopharmaceuticals market are:
• Novartis AG
• Eckert & Ziegler
• ITM Isotope Technologies Munich SE
• SHINE Technologies, LLC
• Actinium Pharmaceuticals, Inc.
• Alpha Tau Medical Ltd.
• ARICEUM THERAPEUTICS
• Bayer AG
• Curium
• IONETIX Corporation
• Isotopia
• Lantheus
• Lilly
• Niowave
• NMR
• Orano Group
• Telix Pharmaceuticals Limited

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 35
1.1 OBJECTIVES OF THE STUDY 35
1.2 MARKET DEFINITION 35
1.3 OVERVIEW OF NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET 35
1.4 MARKETS COVERED 37
2 MARKET SEGMENTATION 40
2.1 MARKETS COVERED 40
2.2 GEOGRAPHICAL SCOPE 41
2.3 YEARS CONSIDERED FOR THE STUDY 42
2.4 CURRENCY AND PRICING 42
2.5 DBMR TRIPOD DATA VALIDATION MODEL 43
2.6 MULTIVARIATE MODELLING 46
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 47
2.8 DBMR MARKET POSITION GRID 48
2.9 VENDOR SHARE ANALYSIS 49
2.10 END USER MARKET COVERAGE GRID 50
2.11 SECONDARY SOURCES 51
2.12 ASSUMPTIONS 51
3 EXECUTIVE SUMMARY 52
4 PREMIUM INSIGHT 58
4.1 PORTER’S FIVE FORCES 59
4.2 PESTEL ANALYSIS 60
4.3 PIPELINE 61
4.4 SUPPLY CHAIN ECOSYSTEM 66
4.4.1 PROMINENT COMPANIES 66
4.4.2 SMALL & MEDIUM SIZE COMPANIES 66
4.4.3 END USERS 66
4.5 INDUSTRY INSIGHTS 67
4.5.1 MICRO AND MACRO ECONOMIC FACTORS 67
4.5.2 KEY PRICING STRATEGIES 68
4.6 MARKETED DRUG ANALYSIS 69
4.6.1 DRUG 69
4.6.1.1 BRAND NAME 69
4.6.1.2 GENERIC NAME 69
4.6.2 THERAPEUTIC INDICATION 69
4.6.3 PHARMACOLOGICAL CLASS OF THE DRUG 69
4.6.4 DRUG PRIMARY INDICATION 69
4.6.5 MARKET STATUS 69
4.6.6 MEDICATION TYPE 70
4.6.7 DRUG DOSAGE FORM 70
4.6.8 DOSAGES AVAILABILITY 70
4.6.9 PACKAGING TYPE 70
4.6.10 DRUG ROUTE OF ADMINISTRATION 70
4.6.11 DOSING FREQUENCY 70
4.6.12 DRUG INSIGHT 70
4.6.13 OVERVIEW OF DRUG DEVELOPMENT ACTIVITIES 71
4.6.13.1 FORECAST MARKET OUTLOOK 71
4.6.13.2 CROSS COMPETITION 71
4.6.13.3 THERAPEUTIC PORTFOLIO 71
4.6.13.4 CURRENT DEVELOPMENT SCENARIO 71
4.7 HEALTHCARE TARIFFS IMPACT ANALYSIS 72
4.7.1 OVERVIEW 72
4.7.2 TARIFF STRUCTURES 72
4.7.2.1 NORTH AMERICA VS. REGIONAL TARIFF STRUCTURES 72
4.7.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES, CMS PRICING MODELS 72
4.7.2.3 EUROPEAN UNION: CROSS-BORDER TARIFF REGULATIONS, REIMBURSEMENT POLICIES 72
4.7.2.4 ASIA-PACIFIC: GOVERNMENT-IMPOSED TARIFFS ON IMPORTED MEDICAL PRODUCTS 72
4.7.2.5 EMERGING MARKETS: CHALLENGES IN TARIFF IMPLEMENTATION 73
4.7.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS 73
4.7.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS 73
4.7.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS 73
4.7.3.3 KEY TRADE AGREEMENTS AFFECTING PHARMACEUTICAL TARIFFS 73
4.8 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS 73
4.8.1.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES 73
4.8.1.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE 73
4.8.1.3 TARIFFS AND THEIR ROLE IN MEDICAL TOURISM 74
4.8.2 TRADE AGREEMENTS AND HEALTHCARE TARIFFS 74
4.8.2.1 WTO REGULATIONS ON HEALTHCARE TARIFFS 74
4.8.2.2 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN 74
4.8.2.3 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS 74
4.8.3 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY 74
4.8.4 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 74
4.9 EPIDEMIOLOGY OVERVIEW 75
4.9.1 INCIDENCE OF ALL CANCERS BY GENDER 75
4.9.2 TREATMENT RATE 76
4.9.3 MORTALITY RATE 76
4.9.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 77
4.9.5 PATIENT TREATMENT SUCCESS RATES 77
5 REGULATORY FRAMEWORK 79
5.1 REGULATORY FRAMEWORK OVERVIEW FOR THE NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET 79
5.1.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL 79
5.1.2 REGULATORY APPROVAL PATHWAYS 80
5.1.3 LICENSING AND REGISTRATION 80
5.1.4 POST-MARKETING SURVEILLANCE 80
5.1.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 80
6 MARKET OVERVIEW 87
6.1 DRIVERS 89
6.1.1 INCREASED EFFICACY OF TARGETED ALPHA AND BETA THERAPIES 89
6.1.2 GROWING ADOPTION OF THERANOSTICS IN PERSONALIZED MEDICINE 89
6.1.3 RISING CLINICAL DEMAND FOR ALPHA-BASED RADIOTHERAPIES 90
6.1.4 RISING CHRONIC DISEASE BURDEN DRIVING RADIOPHARMACEUTICAL DEMAND 91
6.2 RESTRAINTS 92
6.2.1 SUPPLY CHAIN AND SCALABILITY CHALLENGES FROM SHORT ISOTOPE HALF-LIVES 92
6.2.2 STRINGENT REGULATORY LANDSCAPE LIMITING MARKET FLEXIBILITY 92
6.2.3 SAFETY AND EXPOSURE RISKS IN RADIOPHARMACEUTICAL USE 93
6.3 OPPORTUNITIES 94
6.3.1 SURGE IN R&D ACTIVITY EXPANDING RADIOPHARMACEUTICAL APPLICATIONS 94
6.3.2 EXPANSION OF LU-177-PSMA THERAPY IN PROSTATE CANCER TREATMENT 95
6.3.3 STRATEGIC COLLABORATIONS DRIVING RADIOPHARMACEUTICAL INNOVATION 95
6.4 CHALLENGES 96
6.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS 96
6.4.2 SHORTAGE OF SKILLED WORKFORCE IN NUCLEAR MEDICINE AND RADIOCHEMISTRY 97
7 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE 99
7.1 OVERVIEW 100
7.2 BETA EMITTERS 103
7.2.1 LUTETIUM-177 103
7.2.2 TERBIUM-161 103
7.3 ALPHA EMITTERS 104
7.3.1 ACTINIUM-225 104
7.3.2 LEAD -212 104
8 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES 105
8.1 OVERVIEW 106
8.2 REACTOR-PRODUCED ISOTOPES 109
8.3 GENERATOR-PRODUCED ISOTOPES 109
8.4 OTHERS 110
9 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION 111
9.1 OVERVIEW 112
9.2 ONCOLOGY 115
9.2.1 PROSTATE CANCER 116
9.2.2 NEUROENDOCRINE TUMORS 116
9.2.3 LIVER CANCER 116
9.2.4 BRAIN TUMORS 116
9.2.5 BREAST CANCER 116
9.2.6 LEUKEMIA 116
9.3 OTHERS 116
10 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE 117
10.1 OVERVIEW 118
10.2 SMALL MOLECULE LIGANDS 121
10.3 PEPTIDES 121
10.4 MONOCLONAL ANTIBODIES 122
10.5 OTHERS 122
11 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER 123
11.1 OVERVIEW 124
11.2 HOSPITALS 127
11.2.1 ONCOLOGY CENTERS 127
11.2.2 NUCLEAR MEDICINE DEPARTMENTS 127
11.3 RADIOPHARMACIES 128
11.4 RESEARCH INSTITUTES 128
12 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION 129
12.1 NORTH AMERICA 131
12.1.1 U.S. 135
12.1.2 CANADA 138
12.1.3 MEXICO 141
13 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE 144
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS 145
15 COMPANY PROFILES 146
15.1 NOVARTIS AG 146
15.1.1 COMPANY SNAPSHOT 146
15.1.2 REVENUE ANALYSIS 147
15.1.3 COMPANY SHARE ANALYSIS 147
15.1.4 PRODUCT PORTFOLIO 148
15.1.5 RECENT DEVELOPMENTS 148
15.2 ECKERT & ZIEGLER 149
15.2.1 COMPANY SNAPSHOT 149
15.2.2 REVENUE ANALYSIS 149
15.2.3 COMPANY SHARE ANALYSIS 150
15.2.4 PRODUCT PORTFOLIO 150
15.2.5 RECENT DEVELOPMENTS 151
15.3 ITM ISOTOPE TECHNOLOGIES MUNICH SE 152
15.3.1 COMPANY SNAPSHOT 152
15.3.2 COMPANY SHARE ANALYSIS 152
15.3.3 PRODUCT PORTFOLIO 153
15.3.4 RECENT DEVELOPMENT 153
15.4 SHINE TECHNOLOGIES, LLC 154
15.4.1 COMPANY SNAPSHOT 154
15.4.2 COMPANY SHARE ANALYSIS 154
15.4.3 PRODUCT PORTFOLIO 155
15.4.4 RECENT DEVELOPMENT 155
15.5 ACTINIUM PHARMACEUTICALS, INC. 156
15.5.1 COMPANY SNAPSHOT 156
15.5.2 PIPELINE PRODUCT PORTFOLIO 156
15.5.3 RECENT DEVELOPMENTS 157
15.6 ALPHA TAU MEDICAL LTD. 158
15.6.1 COMPANY SNAPSHOT 158
15.6.2 PIPELINE PRODUCT PORTFOLIO 158
15.6.3 RECENT DEVELOPMENT 158
15.7 ARICEUM THERAPEUTICS 159
15.7.1 COMPANY SNAPSHOT 159
15.7.2 PIPELINE PRODUCT PORTFOLIO 159
15.7.3 RECENT DEVELOPMENT 159
15.8 BAYER AG 160
15.8.1 COMPANY SNAPSHOT 160
15.8.2 REVENUE ANALYSIS 160
15.8.3 PIPELINE PRODUCT PORTFOLIO 161
15.8.4 RECENT DEVELOPMENT 161
15.9 CURIUM 162
15.9.1 COMPANY SNAPSHOT 162
15.9.2 PIPELINE PRODUCT PORTFOLIO 162
15.9.3 RECENT DEVELOPMENT 162
15.10 IONETIX CORPORATION 163
15.10.1 COMPANY SNAPSHOT 163
15.10.2 PIPELINE PRODUCT PORTFOLIO 163
15.10.3 RECENT DEVELOPMENT 163
15.11 ISOTOPIA 164
15.11.1 COMPANY SNAPSHOT 164
15.11.2 PIPELINE PRODUCT PORTFOLIO 164
15.11.3 RECENT DEVELOPMENT 164
15.12 LANTHEUS 165
15.12.1 COMPANY SNAPSHOT 165
15.12.2 REVENUE ANALYSIS 165
15.12.3 PIPELINE PRODUCT PORTFOLIO 166
15.12.4 RECENT DEVELOPMENT 167
15.13 LILLY 168
15.13.1 COMPANY SNAPSHOT 168
15.13.2 REVENUE ANALYSIS 168
15.13.3 PIPELINE PRODUCT PORTFOLIO 169
15.14 NIOWAVE 170
15.14.1 COMPANY SNAPSHOT 170
15.14.2 PIPELINE PRODUCT PORTFOLIO 170
15.14.3 RECENT DEVELOPMENT 170
15.15 NMR 171
15.15.1 COMPANY SNAPSHOT 171
15.15.2 PIPELINE PRODUCT PORTFOLIO 171
15.15.3 RECENT DEVELOPMENT 171
15.16 ONCOINVENT 172
15.16.1 COMPANY SNAPSHOT 172
15.16.2 PIPELINE PRODUCT PORTFOLIO 172
15.16.3 RECENT DEVELOPMENT 172
15.17 ORANO GROUP 173
15.17.1 COMPANY SNAPSHOT 173
15.17.2 REVENUE ANALYSIS 173
15.17.3 PIPELINE PRODUCT PORTFOLIO 174
15.17.4 RECENT DEVELOPMENT 175
15.18 RADIOPHARM THERANOSTICS LIMITED 176
15.18.1 COMPANY SNAPSHOT 176
15.18.2 PIPELINE PRODUCT PORTFOLIO 176
15.18.3 RECENT DEVELOPMENT 177
15.19 TELIX PHARMACEUTICALS LIMITED 178
15.19.1 COMPANY SNAPSHOT 178
15.19.2 REVENUE ANALYSIS 178
15.19.3 PIPELINE PRODUCT PORTFOLIO 179
15.19.4 RECENT DEVELOPMENT 180
15.20 TERTHERA 181
15.20.1 COMPANY SNAPSHOT 181
15.20.2 PIPELINE PRODUCT PORTFOLIO 181
15.20.3 RECENT DEVELOPMENT 181
15.20.4 RECENT DEVELOPMENT 181
16 QUESTIONNAIRE 182
17 RELATED REPORTS 185